[New therapies in metastatic castration resistant prostate cancer]

Area of Science:

• Oncology
• Pharmacology

Context:

• The therapeutic options for prostate cancer have significantly expanded.
• New hormonal therapies like abiraterone acetate and enzalutamide have transformed metastatic castration-resistant prostate cancer (mCRPC) treatment.

Purpose:

• To review the expanding therapeutic landscape in prostate cancer.
• To highlight the need for predictive markers to guide treatment sequencing.

Summary:

• Several novel treatments targeting various pathways, including the androgen pathway (e.g., TAK-007, ARN-509), immune system (e.g., sipuleucel, ipilimumab), and tumor cells (e.g., PARP inhibitors, cabozantinib), are under investigation.
• The increasing number of treatment options presents challenges in determining optimal sequencing.
• Identifying predictive markers of response is essential for personalized treatment strategies in mCRPC.

Impact:

• This research underscores the growing complexity of prostate cancer management.
• It emphasizes the critical need for biomarkers to personalize therapy and improve patient outcomes.
• The findings will aid clinicians in navigating treatment decisions for advanced prostate cancer.